VanEck Associates
IMDX

VanEck Associates’s Insight Molecular Diagnostics IMDX Stock Holding History

VanEck Associates’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-879
Closed -$24K – 1034
2020
Q3 		$24K Buy
879
+19
+2% +$545 ﹤0.01% 984
2020
Q2 		$33K Buy
+860
New +$44.4K ﹤0.01% 942

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

VanEck Associates's IMDX Position: Q4 2020 in Review

VanEck Associates sold out of Insight Molecular Diagnostics (IMDX) in Q4 2020, closing a stake of 879 shares — an estimated $24K sold.

VanEck Associates first reported a position in IMDX in Q2 2020 and held it in 2 quarters. The position peaked at $33K in Q2 2020. 60 funds tracked by Wall St. Rank hold IMDX as of Q4 2020.

  • VanEck Associates reported no remaining Insight Molecular Diagnostics position as of Q4 2020 after selling out during the quarter.
  • VanEck Associates sold 879 Insight Molecular Diagnostics shares in Q4 2020, an estimated $24K.
  • VanEck Associates first reported a position in Insight Molecular Diagnostics in Q2 2020 and held it in 2 quarters.
  • VanEck Associates's Insight Molecular Diagnostics position peaked at $33K in Q2 2020.
  • 60 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q4 2020.

Based on VanEck Associates's 13F filing for Q4 2020, filed 9 Feb 2021.